Integra Lifesciences Holdings (IART) Cash & Current Investments (2016 - 2025)
Integra Lifesciences Holdings (IART) has disclosed Cash & Current Investments for 17 consecutive years, with $263.7 million as the latest value for Q4 2025.
- Quarterly Cash & Current Investments fell 3.59% to $263.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $263.7 million through Dec 2025, down 3.59% year-over-year, with the annual reading at $263.7 million for FY2025, 3.59% down from the prior year.
- Cash & Current Investments hit $263.7 million in Q4 2025 for Integra Lifesciences Holdings, down from $267.9 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $663.1 million in Q1 2024 to a low of $253.6 million in Q2 2025.
- Historically, Cash & Current Investments has averaged $369.1 million across 5 years, with a median of $309.1 million in 2023.
- Biggest five-year swings in Cash & Current Investments: surged 115.74% in 2024 and later plummeted 58.79% in 2025.
- Year by year, Cash & Current Investments stood at $513.4 million in 2021, then decreased by 11.06% to $456.7 million in 2022, then crashed by 32.31% to $309.1 million in 2023, then dropped by 11.5% to $273.6 million in 2024, then decreased by 3.59% to $263.7 million in 2025.
- Business Quant data shows Cash & Current Investments for IART at $263.7 million in Q4 2025, $267.9 million in Q3 2025, and $253.6 million in Q2 2025.